Cargando…

Treating Japanese Patients With Pembrolizumab for Platinum-Refractory Advanced Urothelial Carcinoma in Real-World Clinical Practice

BACKGROUND: Since December 2017, pembrolizumab has been approved in Japan as a second-line treatment for radical unresectable urothelial carcinoma (UC) that has become exacerbated after chemotherapy by the international randomized phase 3 trial, KEYNOTE-045. The aim of this study was to evaluate the...

Descripción completa

Detalles Bibliográficos
Autores principales:	Furubayashi, Nobuki, Kuroiwa, Kentaro, Tokuda, Noriaki, Tomoda, Toshihisa, Morokuma, Futoshi, Hori, Yoshifumi, Negishi, Takahito, Inoue, Tomohiro, Kumagai, Masatoshi, Nakamura, Motonobu
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elmer Press 2020
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7239584/ https://www.ncbi.nlm.nih.gov/pubmed/32489505 http://dx.doi.org/10.14740/jocmr4162

Ejemplares similares

Paclitaxel and carboplatin chemotherapy after platinum-based chemotherapy and pembrolizumab for metastatic urothelial carcinoma
por: Furubayashi, Nobuki, et al.
Publicado: (2021)

Organ-Specific Tumor Response to Pembrolizumab in Advanced Urothelial Carcinoma After Platinum-Based Chemotherapy
por: Furubayashi, Nobuki, et al.
Publicado: (2021)

The Association of Clinical Outcomes with Posttreatment Changes in the Relative Eosinophil Counts and Neutrophil-to-Eosinophil Ratio in Patients with Advanced Urothelial Carcinoma Treated with Pembrolizumab
por: Furubayashi, Nobuki, et al.
Publicado: (2021)

The Eosinophil Changes, Efficacy and Safety of Pembrolizumab in Advanced Urothelial Carcinoma Patients with an Older Age and a Poor Performance Status
por: Furubayashi, Nobuki, et al.
Publicado: (2022)

Organ-Specific Therapeutic Effect of Paclitaxel and Carboplatin Chemotherapy After Platinum-Based Chemotherapy and Pembrolizumab for Metastatic Urothelial Carcinoma
por: Furubayashi, Nobuki, et al.
Publicado: (2020)

Association Between Immune-Related Adverse Events and Efficacy and Changes in the Relative Eosinophil Count Among Patients with Advanced Urothelial Carcinoma Treated by Pembrolizumab
por: Furubayashi, Nobuki, et al.
Publicado: (2022)

Timing of changing therapy from gemcitabine and cisplatin chemotherapy based on real-world data of advanced urothelial carcinoma
por: Furubayashi, Nobuki, et al.
Publicado: (2020)

Acute Acalculous Cholecystitis in Patients With Clear Cell Renal Cell Carcinoma Treated With Sunitinib: Report of Two Cases
por: Furubayashi, Nobuki, et al.
Publicado: (2014)

Clinical outcome of transperitoneal ureterocutaneostomy using the transverse mesocolon
por: FURUBAYASHI, NOBUKI, et al.
Publicado: (2013)

Change of genitourinary cancer patients’ perception and expectations over the course of pharmacotherapy
por: Satou, Yoshiaki, et al.
Publicado: (2022)

Relapse of aseptic meningitis induced by ipilimumab and nivolumab therapy for metastatic renal cell carcinoma: A case report
por: Takamatsu, Dai, et al.
Publicado: (2019)

Sarcoid‐like reaction of the extrathoracic lymph node in a patient with lung adenocarcinoma treated with pembrolizumab
por: Takamori, Shinkichi, et al.
Publicado: (2021)

Positive resection margins may not reflect the true margin in patients undergoing radical prostatectomy
por: FURUBAYASHI, NOBUKI, et al.
Publicado: (2014)

Efficacy and safety of third- and fourth-line targeted therapy in Japanese patients with metastatic renal cell carcinoma: A retrospective analysis
por: Takahito, Negishi, et al.
Publicado: (2018)

Biochemical failure after radical prostatectomy in intermediate-risk group men increases with the number of risk factors
por: Furubayashi, Nobuki, et al.
Publicado: (2017)

Radiographical efficacy of systemic treatment for bone metastasis from renal cell carcinoma
por: Negishi, Takahito, et al.
Publicado: (2020)

Eliminating microscopic lymph node metastasis by performing pelvic lymph node dissection during radical prostatectomy for prostate cancer
por: Furubayashi, Nobuki, et al.
Publicado: (2020)

NICE’s rejection of pembrolizumab for platinum-refractory urothelial carcinoma: is there a greater good?
por: Gupta, Shilpa, et al.
Publicado: (2020)

A Case of Cystic Retroperitoneal Dedifferentiated Liposarcoma Diagnosed by Percutaneous Image-Guided Biopsy
por: Morihara, Kaede, et al.
Publicado: (2023)

Author Correction: NICE’s rejection of pembrolizumab for platinum-refractory urothelial carcinoma: is there a greater good?
por: Gupta, Shilpa, et al.
Publicado: (2020)

Concurrent palliative radiation with pembrolizumab for platinum-refractory urothelial carcinoma is associated with improved overall survival
por: Nakamori, Keita, et al.
Publicado: (2022)

A randomized phase 2 trial of pembrolizumab versus pembrolizumab and acalabrutinib in patients with platinum‐resistant metastatic urothelial cancer
por: Zhang, Tian, et al.
Publicado: (2020)

Profile of pembrolizumab in the treatment of patients with unresectable or metastatic urothelial carcinoma
por: Inokuchi, Junichi, et al.
Publicado: (2019)

Efficacy and safety of cabazitaxel therapy in elderly (≥75 years) patients with castration-resistant prostate cancer: A multiinstitutional study
por: Matsumoto, Takashi, et al.
Publicado: (2021)

External Validation of a Prognostic Model Predicting Metastatic Castration-Resistant Prostate Cancer Survival in Patients Receiving Post-Docetaxel Second-Line Chemotherapy
por: Blas, Leandro, et al.
Publicado: (2022)

Efficacy of pembrolizumab rechallenge for metastatic urothelial carcinoma
por: Nishimura, Nobutaka, et al.
Publicado: (2022)

Complete response to pembrolizumab in recurrent nested variant of urothelial carcinoma
por: Fukuta, Kyotaro, et al.
Publicado: (2021)

Favorable response to pembrolizumab in granulocyte colony‐stimulating factor‐producing upper urinary tract urothelial carcinoma
por: Takeda, Hiroki, et al.
Publicado: (2021)

Clinical Impact of Sarcopenia and Inflammatory/Nutritional Markers in Patients with Unresectable Metastatic Urothelial Carcinoma Treated with Pembrolizumab
por: Shimizu, Takuto, et al.
Publicado: (2020)

Pembrolizumab treatment of metastatic urothelial cancer without exacerbating myasthenia gravis
por: Ishii, Akiko, et al.
Publicado: (2020)

Risk stratification for the prognosis of patients with chemoresistant urothelial cancer treated with pembrolizumab
por: Kobayashi, Takashi, et al.
Publicado: (2020)

Paraneoplastic pemphigus manifesting in a patient treated with pembrolizumab for urothelial carcinoma
por: McNally, Michelle A., et al.
Publicado: (2021)

Pembrolizumab plus pemetrexed‐platinum for metastatic nonsquamous non–small‐cell lung cancer: KEYNOTE‐189 Japan Study
por: Horinouchi, Hidehito, et al.
Publicado: (2021)

Emergence of undifferentiated urothelial carcinoma after pembrolizumab treatment for patient with invasive urothelial bladder cancer: A case report
por: Hasegawa, Moto, et al.
Publicado: (2020)

Complete response to pembrolizumab for metastatic urothelial carcinoma in the renal pelvis of allograft kidney
por: Kamei, Jun, et al.
Publicado: (2022)

Phase II trial of cisplatin, gemcitabine and pembrolizumab for platinum-resistant ovarian cancer
por: Walsh, Christine S., et al.
Publicado: (2021)

A radiological complete response to pembrolizumab in a patient with metastatic upper urinary tract urothelial cancer and Lynch syndrome
por: Oki, Ryosuke, et al.
Publicado: (2022)

Off-label use of paclitaxel and pembrolizumab in a case of platinum refractory epithelial ovarian cancer and extensive thromboembolism
por: Lam, Clarissa, et al.
Publicado: (2022)

Organ-Specific and Mixed Responses to Pembrolizumab in Patients with Unresectable or Metastatic Urothelial Carcinoma: A Multicenter Retrospective Study
por: Shimizu, Takuto, et al.
Publicado: (2022)

Pembrolizumab in the treatment of locally advanced or metastatic urothelial carcinoma: clinical trial evidence and experience
por: Crist, Michael, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_v440kjtk53l0e1imm9mp89trvn